Viatris Inc

NASDAQ:VTRS  
10.78
-0.18 (-1.64%)
7:49:02 PM EDT: $10.76 -0.02 (-0.19%)
Other Pre-Announcement

Viatris Announces Two Acquisitions

Published: 11/07/2022 13:49 GMT
Viatris Inc (VTRS) - Viatris Announces Two Acquisitions to Create What It Expects to Be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on Its February 2022 Investor Event.
Viatris Inc - Expects Biocon Biologics Transaction to Close Shortly.
Viatris Inc - Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 Million in Cash.
Viatris Inc - Expects Combination of Acquisitions and Share Repurchases to Be Accretive to Adjusted EPS in 2023 on a Standalone Basis.
Viatris Inc - Anticipates Acquisitions Will Have Potential to Add at Least $1 Billion in Net Sales and at Least $500 Million in Adjusted EBITDA by 2028.
Viatris Inc - Reaffirms Total Pre-tax Proceeds Expected From Biocon Transaction & Certain Non-core Asset Divestitures to Be Up to Approximately $9 Billion.
Viatris Inc - Also Expects to Acquire Famy Life Sciences, Which Has a Complementary Ophthalmology Portfolio.